16 years of historical data (2010–2025) · Real Estate · REIT - Healthcare Facilities
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Sabra Health Care REIT, Inc. trades at 28.3x earnings, 72% below its 5-year average of 101.0x, sitting at the 46th percentile of its historical range. Compared to the Real Estate sector median P/E of 24.1x, the stock trades at a premium of 18%. On a free-cash-flow basis, the stock trades at 13.1x P/FCF, 17% above the 5-year average of 11.2x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $4.6B | $4.6B | $4.1B | $3.3B | $2.9B | $3.0B | $3.6B | $4.0B | $2.9B | $2.0B | $1.6B |
| Enterprise Value | $7.0B | $7.1B | $6.5B | $5.7B | $5.4B | $5.3B | $6.0B | $6.4B | $6.1B | $4.9B | $2.8B |
| P/E Ratio → | 28.31 | 29.59 | 32.07 | 241.46 | — | — | 25.93 | 57.68 | 10.56 | 13.41 | 26.54 |
| P/S Ratio | 5.90 | 5.98 | 5.81 | 5.13 | 4.59 | 5.21 | 6.01 | 6.01 | 4.72 | 4.90 | 6.14 |
| P/B Ratio | 1.57 | 1.64 | 1.49 | 1.19 | 0.94 | 0.88 | 1.06 | 1.15 | 0.90 | 0.58 | 1.58 |
| P/FCF | 13.11 | 13.28 | 13.17 | 11.05 | 9.09 | 9.19 | 14.44 | 10.78 | 6.52 | — | 9.05 |
| P/OCF | 13.11 | 13.28 | 13.17 | 11.05 | 9.09 | 8.32 | 10.15 | 10.78 | 8.21 | 14.88 | 9.05 |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
Sabra Health Care REIT, Inc.'s enterprise value stands at 15.6x EBITDA, 9% above its 5-year average of 14.3x. The Real Estate sector median is 17.0x, placing the stock at a 8% discount on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 9.18 | 9.20 | 8.85 | 8.60 | 9.30 | 9.96 | 9.65 | 9.83 | 11.99 | 10.69 |
| EV / EBITDA | 15.63 | 15.77 | 15.17 | 14.15 | 12.71 | 13.59 | 14.33 | 9.10 | 9.99 | 12.54 | 10.97 |
| EV / EBIT | 26.71 | 26.35 | 26.64 | 44.49 | 184.50 | — | 24.90 | 18.63 | 14.27 | 19.65 | 20.46 |
| EV / FCF | — | 20.39 | 20.84 | 19.05 | 17.01 | 16.41 | 23.93 | 17.31 | 13.56 | — | 15.76 |
Margins and return-on-capital ratios measuring operating efficiency
Sabra Health Care REIT, Inc. earns an operating margin of 34.1%, above the Real Estate sector average of 24.8%. ROE of 5.6% is modest. ROIC of 3.8% represents below-average returns on invested capital.
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 65.0% | 65.0% | 67.7% | 69.8% | 74.0% | 75.2% | 78.0% | 83.6% | 92.1% | 95.6% | 97.8% |
| Operating Margin | 34.1% | 34.1% | 36.5% | 34.2% | 37.6% | 37.0% | — | 79.0% | 49.2% | 55.3% | 61.8% |
| Net Profit Margin | 20.1% | 20.1% | 18.0% | 2.1% | -12.4% | -19.9% | 23.1% | 10.3% | 44.8% | 39.0% | 27.0% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 5.6% | 5.6% | 4.6% | 0.5% | -2.4% | -3.3% | 4.0% | 2.0% | 8.3% | 7.1% | 6.8% |
| ROA | 2.9% | 2.9% | 2.4% | 0.2% | -1.3% | -1.9% | 2.3% | 1.1% | 4.1% | 3.4% | 3.0% |
| ROIC | 3.8% | 3.8% | 3.7% | 3.1% | 3.1% | 2.8% | — | 6.4% | 3.6% | 4.0% | 5.2% |
| ROCE | 5.2% | 5.2% | 5.0% | 4.2% | 4.2% | 3.6% | — | 8.3% | 4.5% | 4.9% | 6.9% |
Solvency and debt-coverage ratios — lower is generally safer
Sabra Health Care REIT, Inc. carries a Debt/EBITDA ratio of 5.7x, which is highly leveraged (29% below the sector average of 7.9x). Net debt stands at $2.5B ($2.6B total debt minus $72M cash). Interest coverage of just 2.4x is concerning — the company has limited headroom to absorb earnings volatility before struggling with debt service.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.90 | 0.90 | 0.89 | 0.87 | 0.83 | 0.72 | 0.71 | 0.71 | 0.99 | 0.99 | 1.19 |
| Debt / EBITDA | 5.66 | 5.66 | 5.73 | 6.04 | 6.03 | 6.27 | 5.84 | 3.50 | 5.27 | 8.75 | 4.77 |
| Net Debt / Equity | — | 0.88 | 0.87 | 0.86 | 0.82 | 0.69 | 0.69 | 0.70 | 0.98 | 0.84 | 1.17 |
| Net Debt / EBITDA | 5.50 | 5.50 | 5.59 | 5.94 | 5.91 | 5.98 | 5.68 | 3.43 | 5.19 | 7.42 | 4.67 |
| Debt / FCF | — | 7.11 | 7.68 | 8.00 | 7.92 | 7.23 | 9.49 | 6.53 | 7.04 | — | 6.70 |
| Interest Coverage | 2.40 | 2.40 | 2.11 | 1.14 | 0.28 | -0.13 | 2.39 | 2.73 | 2.92 | 2.80 | 2.10 |
Short-term solvency ratios and asset-utilisation metrics
The current ratio of 0.56x is below 1.0, meaning current liabilities exceed current assets. The current ratio has declined from 0.78x to 0.56x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.56 | 0.56 | 0.88 | 0.78 | 0.59 | 1.78 | — | — | 3.12 | 8.02 | 4.66 |
| Quick Ratio | 0.56 | 0.56 | 0.88 | 0.78 | 0.59 | 1.78 | — | — | 3.12 | 8.02 | 4.66 |
| Cash Ratio | 0.21 | 0.21 | 0.27 | 0.18 | 0.15 | 0.78 | — | — | 0.53 | 5.06 | 0.65 |
| Asset Turnover | — | 0.14 | 0.13 | 0.12 | 0.11 | 0.10 | 0.10 | 0.11 | 0.09 | 0.06 | 0.11 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Sabra Health Care REIT, Inc. returns 6.5% to shareholders annually primarily through dividends. The payout ratio exceeds 100% at 186.0%, meaning the company is paying out more than it earns — this level is unsustainable long-term without earnings recovery. The earnings yield of 3.5% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | 6.5% | 6.3% | 6.9% | 8.4% | 9.7% | 8.9% | 7.7% | 8.4% | 11.0% | 9.2% | 7.5% |
| Payout Ratio | 186.0% | 186.0% | 221.1% | 2016.9% | — | — | 201.1% | 486.2% | 116.5% | 115.0% | 169.7% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 3.5% | 3.4% | 3.1% | 0.4% | — | — | 3.9% | 1.7% | 9.5% | 7.5% | 3.8% |
| FCF Yield | 7.6% | 7.5% | 7.6% | 9.0% | 11.0% | 10.9% | 6.9% | 9.3% | 15.3% | — | 11.0% |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.1% | 0.2% | 0.0% | 0.0% | 0.0% | 4.9% | 0.0% | 0.0% |
| Total Shareholder Yield | 6.5% | 6.3% | 6.9% | 8.4% | 9.8% | 8.9% | 7.7% | 8.4% | 15.9% | 9.2% | 7.5% |
| Shares Outstanding | — | $244M | $236M | $233M | $231M | $219M | $207M | $188M | $179M | $106M | $66M |
Compare SBRA with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
| $5B | 28.3 | 15.6 | 13.1 | 65.0% | 34.1% | 5.6% | 3.8% | 5.7 | |
| $145B | 148.7 | 64.6 | 50.8 | 39.2% | 3.3% | 2.5% | 0.5% | 8.6 | |
| $39B | 151.1 | 23.2 | 29.5 | -5.9% | 14.2% | 2.1% | 2.5% | 6.0 | |
| $13B | 23.0 | 16.3 | 15.1 | 44.5% | 62.6% | 11.6% | 6.0% | 4.0 | |
| $2B | 14.4 | 16.4 | 13.7 | 75.1% | 48.2% | 10.7% | 5.1% | 5.1 | |
| $9B | 23.6 | 22.9 | 23.1 | 59.1% | 67.2% | 9.2% | 6.1% | 2.2 | |
| $3B | 23.5 | 16.4 | 15.6 | 36.7% | 51.5% | 9.7% | 5.6% | 4.2 | |
| $7B | -27.9 | 16.7 | 54.4 | -33.6% | 8.0% | -4.9% | 0.7% | 6.3 | |
| $14B | 195.6 | 14.7 | 11.9 | 22.5% | 19.3% | 0.8% | 2.3% | 6.5 | |
| $94M | 115.3 | 8.3 | — | — | — | -2.2% | — | — | |
| $498M | 225.2 | 16.2 | 8.8 | 8.7% | 16.7% | 1.1% | 1.6% | 8.4 | |
| Real Estate Median | — | 24.1 | 17.0 | 15.4 | 49.3% | 24.8% | 3.7% | 2.7% | 7.9 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Includes 30+ ratios · 16 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying SBRA stock.
Sabra Health Care REIT, Inc.'s current P/E ratio is 28.3x. The historical average is 32.7x. This places it at the 46th percentile of its historical range.
Sabra Health Care REIT, Inc.'s current EV/EBITDA is 15.6x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 13.2x.
Sabra Health Care REIT, Inc.'s return on equity (ROE) is 5.6%. The historical average is 4.5%.
Based on historical data, Sabra Health Care REIT, Inc. is trading at a P/E of 28.3x. This is at the 46th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Sabra Health Care REIT, Inc.'s current dividend yield is 6.53% with a payout ratio of 186.0%.
Sabra Health Care REIT, Inc. has 65.0% gross margin and 34.1% operating margin. Operating margin above 20% indicates strong pricing power and cost efficiency.
Sabra Health Care REIT, Inc.'s Debt/EBITDA ratio is 5.7x, indicating high leverage. A ratio above 4x may signal elevated financial risk.